Evidence map›Paper›PMID 42897333›Full record

ArticleThe EMBO journal2026

ATP-driven dynamics and itraconazole binding of the drug efflux pump Cdr1 from Candida glabrata.

Jorgaq Pata, Benjamin Wiseman, Eleftherios Zarkadas, Rim Baccouch, Nour Samrouth, Célia Desbois, Loïck Moissonier, Alexis Moreno, Atanu Banerjee, Stéphanie Aguerro and 12 more

Abstract read
PubMed Publisher
In one paragraph

Article in The EMBO journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Jorgaq PataDrug Resistance & Membrane Proteins group, Molecular Microbiology & Structural Biochemistry Laboratory, CNRS - Lyon 1 University 5086, IBCP, Lyon, France.ORCID http://orcid.org/0000-0002-9811-0237
Benjamin Wiseman *Department of Biochemistry and Biophysics, Arrhenius Laboratories for Natural Sciences, Stockholm University, Stockholm, Sweden.ORCID http://orcid.org/0000-0002-2994-5839
Eleftherios Zarkadas *University of Grenoble Alpes, CNRS, CEA, EMBL, IBSG, Grenoble, France.ORCID http://orcid.org/0000-0002-9276-9831
Rim BaccouchDrug Resistance & Membrane Proteins group, Molecular Microbiology & Structural Biochemistry Laboratory, CNRS - Lyon 1 University 5086, IBCP, Lyon, France.
Nour SamrouthDrug Resistance & Membrane Proteins group, Molecular Microbiology & Structural Biochemistry Laboratory, CNRS - Lyon 1 University 5086, IBCP, Lyon, France.
Célia DesboisDrug Resistance & Membrane Proteins group, Molecular Microbiology & Structural Biochemistry Laboratory, CNRS - Lyon 1 University 5086, IBCP, Lyon, France.
Loïck MoissonierDrug Resistance & Membrane Proteins group, Molecular Microbiology & Structural Biochemistry Laboratory, CNRS - Lyon 1 University 5086, IBCP, Lyon, France.ORCID http://orcid.org/0000-0002-7223-9454
Alexis MorenoDrug Resistance & Membrane Proteins group, Molecular Microbiology & Structural Biochemistry Laboratory, CNRS - Lyon 1 University 5086, IBCP, Lyon, France.ORCID http://orcid.org/0000-0002-0952-3540
Atanu BanerjeeAmity Institute of Biotechnology and Amity Institute of Integrative Sciences and Health, Amity University Haryana, Gurgaon, India.ORCID http://orcid.org/0000-0001-9319-4593
Stéphanie AguerroECMO team, Tissue Biology and Therapeutic Engineering Laboratory, CNRS - Lyon 1 University Laboratory 5305, IBCP, Lyon, France.
Emmanuel BettlerECMO team, Tissue Biology and Therapeutic Engineering Laboratory, CNRS - Lyon 1 University Laboratory 5305, IBCP, Lyon, France.ORCID http://orcid.org/0000-0001-8400-8277
Marie DujardinEurofins-CALIXAR, 60 avenue Rockefeller, Lyon, France.
Sandrine MagnardDrug Resistance & Membrane Proteins group, Molecular Microbiology & Structural Biochemistry Laboratory, CNRS - Lyon 1 University 5086, IBCP, Lyon, France.
Raphaël TerreuxECMO team, Tissue Biology and Therapeutic Engineering Laboratory, CNRS - Lyon 1 University Laboratory 5305, IBCP, Lyon, France.
Guy SchoehnUniversity of Grenoble Alpes, CNRS, CEA, EMBL, IBSG, Grenoble, France.ORCID http://orcid.org/0000-0002-1459-3201
Martin HögbomDepartment of Biochemistry and Biophysics, Arrhenius Laboratories for Natural Sciences, Stockholm University, Stockholm, Sweden.ORCID http://orcid.org/0000-0001-5574-9383
Ahcène BoumendjelUniversity of Grenoble Alpes, INSERM, LRB, Grenoble, France.ORCID http://orcid.org/0000-0002-1830-6409
Erwin LampingDepartment of Oral Sciences, Sir John Walsh Research Institute, University of Otago, Dunedin, New Zealand.ORCID http://orcid.org/0000-0002-4942-4782
Richard D CannonDepartment of Oral Sciences, Sir John Walsh Research Institute, University of Otago, Dunedin, New Zealand.
Rajendra PrasadAmity Institute of Biotechnology and Amity Institute of Integrative Sciences and Health, Amity University Haryana, Gurgaon, India.
Vincent ChaptalDrug Resistance & Membrane Proteins group, Molecular Microbiology & Structural Biochemistry Laboratory, CNRS - Lyon 1 University 5086, IBCP, Lyon, France. vincent.chaptal@cnrs.fr.ORCID http://orcid.org/0000-0003-2603-0294
Pierre FalsonDrug Resistance & Membrane Proteins group, Molecular Microbiology & Structural Biochemistry Laboratory, CNRS - Lyon 1 University 5086, IBCP, Lyon, France. pierre.falson@univ-lyon1.fr.ORCID http://orcid.org/0000-0002-9760-4577

Funding

Agence Nationale de la Recherche (ANR) ANR-24-CE44-3527 RESTORConseil Régional d'Auvergne (Auvergne Regional Council) R&D booster-IMABGENFrench Infrastructure for Integrated Structural Biology (FRISBI) ANR-10-INBS-0005-02Instruct ERIC 24618Knut och Alice Wallenbergs Stiftelse (kawforskning) 2023.0201Marsen Fund MFP-UOO2210Swedish research council 2021-03992Université Grenoble Alpes (UGA) GRAL ANR-17-30 EURE-0003
6 · The paper itself

Abstract

Azole resistance in Candida species is often caused by the overexpression of Cdr1. Despite its clinical relevance, the structural basis for its ATP-driven efflux pump function remains elusive. We present four high-resolution cryo-EM structures of Candida glabrata Cdr1 obtained in the absence and presence of ATP-Mg²⁺, itraconazole, and vanadate, capturing distinct nucleotide- and substrate-occupancy states. Additional low-population cryo-EM conformers were unveiled by 3D variability analysis, offering a detailed view of structural transitions linked with ATP-hydrolysis. The motion shows a 4 Å piston-like retraction of the C-helix from the γ-phosphate/vanadate of the hydrolyzed ATP. This causes the nearby transmembrane helix-1 (TMH-1) to open the drug-binding site via lateral displacement and unwinding of the inner-leaflet region of TMH-2. A reverse 'squeeze-and-push' motion of TMH-2 possibly drives substrate extrusion. High-resolution structures also reveal how itraconazole adapts its shape to fit into the drug-binding site. Our findings provide a dynamic structural framework for Cdr1-mediated azole resistance and the conserved chemo-mechanical cycle of ABC proteins, including non-membranous members.

Identifiers

PMID42897333

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.